Acromegaly: a challenging condition to diagnose

Acromegaly is an uncommon, chronic disease, characterized by hypersecretion of a pituitary growth hormone by somatotroph adenomas, along with increased levels of insulin-like growth factor-1. Although acromegaly presents a wide array of clinical manifestations, the salient symptoms include acral and soft tissue enlargement, joint pain, heart and respiratory failure, diabetes mellitus, and hypertension, leading to increased morbidity and mortality. Hence, early diagnosis of the disease is critical to enhance life expectancy and quality of life. New approaches are being developed for diagnosis and surveillance (both screening and follow-up), including sensitive biochemical assays and the use of MRI to visualize extremely small tumors, and are helpful in the early diagnosis of acromegaly, subsequent treatment, and disease control. This mini-review summarizes the most common and effective tools used in the diagnosis of acromegaly.

[1]  C. Awoniyi,et al.  Acromegaly discovered during a routine out-patient surgical procedure: a case report , 2017, Journal of Medical Case Reports.

[2]  A. Tirosh,et al.  Complications of acromegaly: thyroid and colon , 2017, Pituitary.

[3]  S. Lamberts,et al.  Somatostatin analogues in acromegaly and gastroenteropancreatic neuroendocrine tumours: past, present and future. , 2016, Endocrine-related cancer.

[4]  D. Giunta,et al.  Incidence and prevalence of clinically relevant pituitary adenomas: retrospective cohort study in a Health Management Organization in Buenos Aires, Argentina , 2016, Archives of endocrinology and metabolism.

[5]  J. Abucham,et al.  Challenges in the diagnosis and management of acromegaly: a focus on comorbidities , 2016, Pituitary.

[6]  V. Torri,et al.  ACROSCORE: a new and simple tool for the diagnosis of acromegaly, a rare and underdiagnosed disease , 2016, Clinical endocrinology.

[7]  I. Kreitschmann-Andermahr,et al.  Diagnosis and management of acromegaly: the patient’s perspective , 2016, Pituitary.

[8]  K. Mukherjee,et al.  Clinical profile and outcome of patients with acromegaly according to the 2014 consensus guidelines: Impact of a multi-disciplinary team. , 2015, Neurology India.

[9]  P. Rosário,et al.  Laboratory investigation of acromegaly: is basal or random GH > 0.4 µg/L in the presence of normal serum IGF-1 an important result? , 2015, Archives of endocrinology and metabolism.

[10]  G. Baskol,et al.  Increased genome instability and oxidative DNA damage and their association with IGF-1 levels in patients with active acromegaly. , 2014, Growth hormone & IGF research : official journal of the Growth Hormone Research Society and the International IGF Research Society.

[11]  F. Cordido,et al.  Practical guidelines for diagnosis and treatment of acromegaly , 2013 .

[12]  L. Nachtigall,et al.  Acromegaly: the disease, its impact on patients, and managing the burden of long-term treatment , 2013, International journal of general medicine.

[13]  A. Barkan,et al.  The changing face of acromegaly—advances in diagnosis and treatment , 2012, Nature Reviews Endocrinology.

[14]  F. Cordido,et al.  Clinical Manifestations and Diagnosis of Acromegaly , 2012, International journal of endocrinology.

[15]  S. Melmed,et al.  Clinical, quality of life, and economic value of acromegaly disease control , 2011, Pituitary.

[16]  D. Clemmons Consensus statement on the standardization and evaluation of growth hormone and insulin-like growth factor assays. , 2011, Clinical chemistry.

[17]  Z. Karaca,et al.  Micronucleus evaluation in mitogen-stimulated lymphocytes of patients with acromegaly. , 2010, Metabolism: clinical and experimental.

[18]  M. Ragonese,et al.  Increased prevalence of acromegaly in a highly polluted area. , 2010, European journal of endocrinology.

[19]  P. Chanson,et al.  A consensus on criteria for cure of acromegaly. , 2010, The Journal of clinical endocrinology and metabolism.

[20]  J. Bruce,et al.  Features at diagnosis of 324 patients with acromegaly did not change from 1981 to 2006: acromegaly remains under‐recognized and under‐diagnosed , 2010, Clinical endocrinology.

[21]  S. Melmed Acromegaly pathogenesis and treatment. , 2009, The Journal of clinical investigation.

[22]  Michael Buchfelder,et al.  Surgical treatment of pituitary tumours. , 2009, Best practice & research. Clinical endocrinology & metabolism.

[23]  H. Wittchen,et al.  High prevalence of biochemical acromegaly in primary care patients with elevated IGF‐1 levels , 2008, Clinical endocrinology.

[24]  A. Barkan,et al.  Current diagnosis of acromegaly , 2008, Reviews in Endocrine and Metabolic Disorders.

[25]  S. Melmed Medical progress: Acromegaly. , 2006, The New England journal of medicine.

[26]  X. Matías-Guiu,et al.  Acromegaly due to a growth hormone-releasing hormone-secreting intracranial gangliocytoma , 2005, Journal of endocrinological investigation.

[27]  G. Gamble,et al.  Factors influencing mortality in acromegaly. , 2004, The Journal of clinical endocrinology and metabolism.

[28]  G. Brabant Insulin-like growth factor-I: marker for diagnosis of acromegaly and monitoring the efficacy of treatment. , 2003, European journal of endocrinology.

[29]  H. Machado,et al.  Assessment of disease activity in treated acromegalic patients using a sensitive GH assay: should we achieve strict normal GH levels for a biochemical cure? , 2002, The Journal of clinical endocrinology and metabolism.

[30]  L. Brunereau,et al.  Cavernous sinus invasion by pituitary adenoma: MR imaging. , 2000, Radiology.

[31]  M. Jeevanandam,et al.  Pulsatile nature of growth hormone levels in critically ill trauma victims. , 1995, Surgery.